Chemokines have been found to alter tumor growth and metastasis. We previously described that a particular chemokine receptor, CXCR4, was predominantly expressed on various glioma cell lines and in resected glioblastoma specimens. Herein, we have tested the ligand of CXCR4, stromal cell derived factor-1α (SDF-1α, CXCL12), on the response of human glioma cells. We found that SDF-1α increased the expression of membrane type-2 matrix metalloproteinase (MT2-MMP), but not other MT-MMPs, MMP-2 or MMP-9. The SDF-1α enhanced MT2-MMP expression was blocked by a CXCR4 antagonist, AMD3100. Functional invasion assays showed that SDF-1α stimulated glioma cells to invade through matrigel-coated chambers and this effect was 
Introduction
Malignant gliomas are the most common primary brain tumors in humans, accounting for more than 50% of neoplasms that arise within the central nervous system (CNS) The MMPs represent a large family of proteolytic enzymes that play key roles in cancer progression, proliferation, angiogenesis and tumor metastasis. Gelatinase A and B (MMP-2 and MMP-9, respectively) have been well studied in glioma malignancy particularly because these enzymes are easy to measure by gelatin zymography. In this regard, a large body of literature reports that MMP-2 and -9 are upregulated in glioma specimens in vitro and in situ (3-7).
The membrane-type MMPs (MT-MMPs) constitute 6 members of the MMP family that are anchored to cell surfaces either through a transmembrane domain or a glycosylphosphatidylinositol linkage. MT-MMPs are upregulated in many tumor types including gliomas (8) (9) (10) (11) (12) (13) . Functionally, MT1-MMP (MMP-14) has been noted to at Pennsylvania State University on http://carcin.oxfordjournals.org/
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Zhang and Yong 4 promote cell invasion in tumor types such as melanoma (14, 15) , breast cancers (16) and gastric carcinoma (17, 18) .
In recent investigations, we determined that although many tumor types contain high levels of MT-MMPs, these were further elevated in glioma cell lines compared to carcinomas; indeed, there were positive correlations between glioma grade and the mRNA levels of MT1-MMP, MT2-MMP (MMP-15) and MT6-MMP (MMP-25) (13) .
Nonetheless, how these MT-MMPs are regulated in glioma cells, or their functional roles, remain unclear.
Chemokines are a large family of small, secreted chemotactic cytokines which play critical roles in many normal and pathophysiological processes, such as infections and autoinmmune diseases. Chemokines are also implicated in the pathogenesis of a variety of tumors (19) (20) (21) . Several chemokines have been described on glioma cells, including macrophage chemoattractant protein-1 (CCL2) (22) and interleukin-8 (CXCL8) (23) . To address which chemokine may play particularly important roles in glioma characteristics, we analyzed glioma cell lines for specific receptors that are commonly expressed across a majority of glioma lines. In this regard, we described the predominance of CXCR4 and showed that its ligand, CXCL12 (stromal cell derived factor-1, SDF-1), is a survival and chemotatic factor for glioma cells in culture (24) .
While the Akt/protein kinase B pathway was activated in glioma cells and may mediate survival of cells consequent to SDF-1 stimulation, the mechanisms of SDF-1-CXCR4 interaction in glioma that lead to the altered motility of cells remain unclear.
In this study, we have investigated the mechanisms consequent to SDF-1-CXCR4 interactions that mediate glioma invasiveness. We report that SDF-1α stimulated the 
Materials and Methods

Glioma Cell Culture and Resected Glioma Specimens
LN827 and U373 are established human glioma cell lines that were used in most experiments in this study; in some cases, LN215, LN308 and LN992 were also utilized.
These cell lines were chosen based on their expression of CXCR4 transcripts as determined previously (24) . All lines were maintained in medium containing 10% fetal calf serum (FCS) (24) , which was also the medium used during in vitro experiments. Six resected glioma specimens were from patients with glioblastoma multiforme, and histological confirmation of the grade of malignancy was obtained by sampling sections from these tumors (24) . We were not informed of the treatment history or clinical presentation (e.g. recurrent tumor) of these patients, in order to respect privacy laws.
Non-transformed brain tissues were from patients with epilepsy and these were normal appearing tissues that were resected in order to access and remove epileptogenic foci.
Real Time Quantitative polymerase chain reaction (PCR)
For RNA isolation, cells at 80% confluency in 6-well plates, treated with recombinant SDF-1α (R&D system) or saline vehicle, were lysed in 1ml TRIzol 
Flow cytometry
Cells at 80% confluence in 100-mm dishes were detached with 2 ml of Versene (Invitrogen) for 10min and were washed with cold Hanks' balanced salt solution twice.
Cells were then incubated with a monoclonal anti-human MT2-MMP antibody directly conjugated to phycoerythrin (R&D systems) for 45 min on ice in the dark. The cells were washed, fixed and analyzed by flow cytometry.
Western Blot
To determine the total cellular content of MT2-MMP, glioma cells were treated with SDF-1α (100ng/ml) for 24 hours. Cell lysates were then generated in lysis buffer (24) , collected, freeze-thawed twice, and spun at 13,000 rpm at 4ûC for 10min. The total (1:1000) was applied overnight at 4ûC followed by goat anti mouse IgG for 1h at room temperature. All antibodies were diluted in PBS containing 0.1% Tween 20 and 3% milk. ECL (Amersham Biosciences) was used for immunodetection.
Gelatin zymography
To detect MMP-2 and -9, gelatin zymography of the conditioned medium of cells was performed as described previously (24) . transfected by Lipofectamine (Invitrogen). G418 (500 µg/ml, Calbiochem) was added to the cells 48h after transfection to select for positive clones.
RNA interference
Cell Invasion Assay
Human glioma cell invasion was evaluated using Matrigel coated boyden chamber with 8 µm pore size (BD Biosciences, Two Oak Park, Bedford, MA). Matrigel was diluted with cold DMEM (1:3) and then gelled in 24 well insert by incubating at 37ûC for at least 1h. A 0.5ml aliquot of glioma cell suspension at 5x10 4 cells/ml in 2.5% FCScontaining glioma medium was seeded on the upper chamber of each well, while 1 ml of 10% FCS-containing glioma medium was added to the lower chamber; the higher serum content in the lower chamber acted as a chemotactic gradient. Cells were left to invade for 20h. Non-invading cells that remained on the upper surface of the filter were removed by a cotton swab, and cells that remained adherent to the underside of membrane were fixed in 95% ethanol/5% acetic acid for 15 min followed by hematoxylin staining for 10 min. The membrane was then cut off, mounted and the number of migrated cells was counted using a microscope. Six contiguous fields through the equatorial axis viewed using a 40x objective were examined to obtain representative number of cells in each set.
Cell growth curve
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Ten thousand glioma cells were seeded into each well of 24 well plates. At 1, 2, 3 and 4 days, adherent cells were detached by 0.25% trypsin, collected and total cell numbers were counted using a Z2 Coulter Counter. Cell numbers were plotted against the time points, giving rise to the growth curve of cells.
Implantation of tumor cells: assessment of survival of recipients and tumor size
Two MT2-MMP downregulated LN827 cell clones (clone1 and 2), wildtype (wt)
LN827 cells, and non-specific siRNA control cells were trypsinized, washed in PBS once and resuspended in PBS at a concentration of 2.5 x 10 7 /ml. Four µl (1x10 5 cells) of each preparation was injected stereotaxically into the right striatum of each anesthetized nude mouse (n of 6 per group per experiment). Animals were then sutured and returned to their cages and allowed free access to food and water. Animals were weighed every other day and any symptoms of neurological deficit were recorded. The occurrence of death was recorded so as to obtain data for the Kaplan-Meier survival curve. In accordance with ethical practice, mice that were moribund (negligible limb movement and loss of body weight exceeding 20%) were also considered dead and were sacrificed. Two survival curves, representing 2 separate experiments conducted at different times, were tabulated ( Fig. 6E,F) .
In another set of experiments, 6 mice each of the non-specific siRNA control group or implanted with MT2-MMP downregulated clones were sacrificed 21 days after implantation to address tumor growth in the brain prior to the appearance of symptoms.
To assess tumor growth in the brain, the whole brain was removed from mice at sacrifice, cut into defined blocks, fixed in formalin and embedded in paraffin. Six µm 
Statistics
The one-way ANOVA test was used to compare multiple group data while the unpaired Student's T-test was used to compare two groups of data. P<0.05 was considered as statistically significant. 
Results
Selective increase of MT2-MMP following SDF-1α simulation of glioma cells
We tested the responsiveness of the LN827 and U373 glioma cell lines to SDF-1α. Figure 1 demonstrates that SDF-1α increased the expression of transcripts encoding MT2-MMP in both lines. This occurred at 100 ng/ml but not at lower concentrations, in agreement with our previous observations that high concentrations of this chemokine are required to produce responses in glioma lines (24) .
In contrast to MT2-MMP, other MT-MMP transcripts measured were not altered by SDF-1α. This was the case for MT1, MT3 and MT5-MMP (Fig. 1C) ; we could not reliably assess MT4 and MT6-MMP in these cells due to technical difficulties.
Further selectivity of SDF-1α for MT2-MMP was demonstrated by the inability of this chemokine to alter the protein levels of MMP-2 and -9 ( Fig. 1D) , which are commonly studied in glioma biology as noted earlier (3-7), and of two growth factors that are of significance to glioma cells: VEGF and HGF (Fig.1E ).
Thus, of various transcripts investigated, SDF-1α selectively increased MT2-MMP in glioma cells. The presence of the CXCR4 antagonist, AMD3100 (AnorMed, British Columbia, Canada), added 1h before SDF-1α, abolished this effect, suggesting that the SDF-1α enhanced MT2-MMP transcript is through the CXCR4 receptor (Fig.   1F ).
To determine whether the effect on MT2-MMP transcripts was also reflected in alteration of protein content, and because MT2-MMP would act extracellularly, we analyzed the cell surface expression of MT2-MMP on glioma cells using flow cytometry. as assessed using western blot analysis (Fig. 2B ).
In correspondence with cell lines in culture, resected glioma specimens also demonstrated significant elevations of MT2-MMP when compared to non-tranformed brain samples (Fig. 2C and 2D ).
SDF-1α stimulates invasiveness of glioma cells in vitro through MT2-MMP
In matrigel invasion assays, SDF-1α increased the capacity of glioma cells to invade and this was the case for both lines tested, LN827 and U373 (Fig. 3) .
To evaluate whether SDF-1 and MT2-MMP were related functionally for invasive capacity, stable clones with downregulated expression of MT2-MMP at the level of transcripts ( Fig. 4A ) and protein ( Fig. 4B) were generated for the LN827 line using RNA interference. The siRNA to MT2-MMP did not modulate the expression of other MTMMPs evaluated (Fig. 4C) , or of the gelatinases, MMP-2 and -9 (Fig. 4D) . The MT2-MMP siRNA clones grew normally and growth curves over 4 days in vitro matched those of control cells with non-specific siRNA (Fig. 4E) .
The capacity of MT2-MMP down-regulated clones to invade across matrigel was investigated. Compared to non-specific siRNA control cells, MT2-MMP siRNA clones 1 and 2 both had decreased capacity to invade under basal conditions (Fig. 5A) .
Furthermore, when stimulated with SDF-1α, whereby control cells increased their invasiveness, MT2-MMP down-regulated clones 1 and 2 did not (Fig. 5B) . 
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Collectively, these results suggest that the effect of SDF-1α in promoting glioma invasiveness was through an MT2-MMP mediated mechanism. Furthermore, under basal conditions, the invasiveness of glioma cells was also decreased in cells that had low expression of MT2-MMP.
MT2-MMP siRNA clones have reduced tumorigenicity in vivo
We implanted the LN827 glioma cells into the striatum of nude mice. One batch of mice was sacrificed 21 days after implantation, before animals were symptomatic and before any weight loss was evident. Using hematoxylin and eosin stain, tumors were detected in all animals examined (n of 6 non-specific siRNA controls, and n of 6 mice given MT2-MMP siRNA clone 2). The nature of the tumors growing intracerebrally was qualitatively different between control non-specific siRNA cells and Clone 2 cells.
While the control glioma cells had invasive fingers which arborized from the main tumor mass in several directions ( Fig. 6A and C) , the MT2-MMP siRNA cells grew as a discrete mass with well delineated borders ( Fig. 6B and D) .
In the mice sacrificed at 21 days after implantation, tumor size was generally smaller in the brain of animals implanted with the MT2-MMP siRNA clones.
Measurement of maximal tumor area in sections from 6 brains implanted with nonspecific siRNA control cells revealed a size of 0.50 ± 0.09 mm 2 (mean ± SEM); in contrast, this was 0.31 ± 0.08 in clone 2 implanted brains (n of 6 mice), representing a decrease in tumor size of 40%.
Mice were also monitored for survival in response to the implanted cells. Figure   6E shows that while non-specific siRNA control cells produced death to mice (6/6) In a second survival experiment (Fig. 6F) , when all mice in the non-specific siRNA control group were dead at 45 days of implantation, 6 of 6 mice given MT2-MMP siRNA clone 2 were still alive at day 58, when the experiment was terminated.
In both survival experiments, we did not determine tumor size at the end-points of death from tumor since the brains generally had large tumor mass in all groups that accounted for their death.
In summary, siRNA down-regulation of MT2-MMP in the LN827 line rendered the glioma cells with less evidence of invasive capacity in vivo, and survival of mice was prolonged. 
Discussion
There is substantial evidence that the family of MMPs is important for various aspects of glioma activity. In particular, the gelatinase MMP members (MMP-2 and -9)
have received attention and their levels are upregulated in glioma tissues compared to normal samples; glioma cell lines express high amounts of MMP-2 and -9 that correlate with several properties of their increased tumorigenicity (3, 7, 25, 26) . for MT1-MMP in gliomas. In this regard, glioma cells secrete MT1-MMP that helps them migrate on myelin (38) , and the over-expression of MT1-MMP in glioma cells increased motility through a mechanism that involved cell surface tissue transglutaminase (39) . MT1-MMP may also mediate the angiogenesis that is facilitated in gliomaendothelial cell co-culture (40). Furthermore, a mechanism for epidermal growth factor receptor-mediated invasiveness of glioma cells appears to be through MT1-MMP induction (41).
In the current examination, we have uncovered a hitherto unknown role for MT2-MMP in glioma activity. We found that MT2-MMP down-regulation decreases the basal rate of invasiveness of glioma cells across matrigel, and that clones stably underexpressing MT2-MMP grew less well in the brain of nude mice and did not confer death to animals to the same extent as control cells (Fig. 6 ). This was evident in 2 experiments (Fig. 6E,F) and, although the lack of pathogenecity of clone 2 MT2-MMP siRNA cells was more pronounced in the second set (F) than in an earlier series (E), the trend was similar towards a longer survival time in MT2-MMP siRNA clones compared to nonspecific siRNA controls. It would be of interest to evaluate whether CXCR4 or SDF-1α expression is altered in vivo in the brains of these transfectants. Overall, the specific inhibition of MT2-MMP may improve the targeting of glioma cells in future trials.
Significantly, we found that the regulation of MT2-MMP in responsive lines was through another system important in glioma biology, the chemokines. While originally described in the context of directing leukocyte trafficking, chemokines are now known to have important growth and tumor promoting activity (19) (20) (21) . A pivotal observation has been the finding that the CXCR4 receptor and its ligand, SDF-1α, play a major role in guiding metastatic breast cancer cells to the lung (20) . The interaction of CXCR4 -SDF-1α is now documented to be important in at least 23 tumor types (21) . Attention in glioma cells has also focused on SDF-1α since the CXCR4 receptor is commonly expressed in glioma specimens (24) , where its levels may be regulated by cytokines (42) .
Indeed, SDF-1 and CXCR4 have been found co-localized in human glioblastoma tissues, in regions of angiogenesis, and a role for this system in angiogenesis has been proposed (43, 44) . In vitro, SDF-1α induces proliferation in a dose-dependent manner in glioma cell lines (45) . Thus, the current results that SDF-1α regulates MT2-MMP expression, which is blocked by AMD3100, to mediate glioma invasiveness emphasize the importance of inhibiting the CXCR4 receptor that we have documented to be commonly expressed in glioma lines (24) . Along this line, the systemic administration of the AMD3100, inhibits the growth of U87 glioblastoma xenografts implanted intracranially in mice (46).
We note that the SDF-1α enhanced expression of MT2-MMP was not a universal
phenomenon of all glioma lines tested. While this occurred in the LN827 and U373 lines (Fig. 1) , and also in the LN215 line, no upregulation was seen in the LN308 or LN992
lines (data not shown). All of these lines have CXCR4 transcripts (24) but it is possible that the CXCR4 signaling cascade is not coupled to the receptor in non-responsive lines.
Our previous work using 20 and 50 ng/ml SDF-1α (24) did not result in SDF-1α
increasing the invasiveness of glioma cells across matrigel. In the current experiment, 100 ng/ml of this chemokine had to be used to effect invasion across matrigel (Fig. 4) , and this is correspondent with the finding that 100 ng/ml is required to increase MT2-MMP expression (Fig. 1) . to non-specific siRNA controls (n of 6 each) (E); the non-specific siRNA cells did not differ from wildtype LN827 cells in causing demise to mice (data not shown).
Finally, in a second set of experiments where all 6 mice implanted with non-specific siRNA control cells were dead at 45 days, 6 of 6 mice given MT2-MMP siRNA clone 2 were still alive at termination of experiment (day 58).
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